Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. announced top-line data today from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic, polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... Study Ingredient,s, Impact on North Americans, NEW ... of,Japan today announced that it has selected world-renowned Cardiologist ... KGK Synergize Inc.,to launch a new clinical trial to ... lipid management and the reduction of cardiovascular,risk factors in ...
... a 52-week phase 3,study (LEADTM 3) of Novo ... GLP-1 analog, were published online today in The ... produces statistically,significant and sustained improvements in blood sugar ... compared with glimepiride, a widely used,oral anti-diabetic drug. ...
Cached Medicine Technology:Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 2Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels 3Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 2Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet 3
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... depression may increase the risk for stroke, a new study ... the risk of a stroke or a transient ischemic ... apparently raised stroke or TIA risk by 59 percent. And ... a mini-stroke caused by a temporary blockage of blood flow ...
(Date:7/11/2014)... the distinguished wedding dress manufacturer and retailer, has recently ... . To top it all off, all these high ... to 65% off. Clients who place orders on the ... Fadhits.com is devoted to designing and selling beautiful wedding ... All its items come with very fast delivery. More ...
(Date:7/11/2014)... San Francisco shows that an "expressive therapy" group ... living with HIV disclose their health status and ... and quality of their relationships., "Medication alone is ... L. Machtinger, MD, director of the Women,s HIV ... patients are on effective antiretroviral therapy but far ...
(Date:7/11/2014)... 11, 2014 Bedros Keuilian is known in ... he’s earned by founding the fast-selling fitness franchise in the ... businesses. He works with successful boot camp owners on a ... the traits of the most successful boot camp owners , ... qualities. , “I’ve worked with and coached some of the ...
(Date:7/11/2014)... When the mercury rises, heat can strain the limits of ... on a heavier load in hot weather to keep body ... Harvard Men's Health Watch . , For otherwise fit, ... their limits and drinking enough fluids. But what about men ... to the heat," says Dr. Joanne Foody, Director of cardiovascular ...
Breaking Medicine News(10 mins):Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Elegant Lace Holiday Dresses Released by Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3
... is a form of arthritis where one or more ... in these type of joint problems is the loss ... that moisturizes the area. This fluid is called synovial ... since 1987, after the therapy was proved beneficial in// ...
... Institute, has succeeded in finding a new biosensor ... a breakthrough technology that will help scientific researchers ... of neurons, nerve tissue and organic neural networks. ... metal oxide semiconductor technology extended with additional process ...
... currently testing the safety of hypothermia as a ... treatment has been shown to be effective for ... effectiveness in treating children with traumatic brain injuries ... excitotoxicity (excessive neurotransmitters released with injury that damage ...
... of Durham in England has reported a discovery, that adds ... ones, for breast feeding of babies. Babies who are breast-fed ... than babies who are bottle-fed in bed. The study included ... while they slept. Researchers found that mothers who breast-fed their ...
... received a patient, a two-month-old baby with white blood! The ... caused due to a deficiency of lipoprotein lipase. This disease ... said that the baby was brought to the hospital with ... boy child, was found to have lipemic blood. Doctors said ...
... study published in the journal, Molecular Psychiatry suggested that scientists ... to sleepwalking. Sleepwalking is a complex disorder and affects around ... of adults. Though the condition is harmless, it may sometimes ... others. Scientists examined a family of genes known as HLA ...
Cached Medicine News:
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: